Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.50 |
| ▸ | MEN1 | O00255 | 9/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5153634 | 0.91 | MAPT (0.51) | MAPTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL6037562 | 0.88 | ITGA4 (0.56) | MAPTMEN1KMT2AITGB1ITGA4 | |
| SCHEMBL5152596 | 0.87 | LPAR1 (0.47) | MAPTMEN1KMT2AALDH1A1ITGB1 | |
| SCHEMBL5152837 | 0.86 | BRD4 (0.54) | MAPTMEN1KMT2AITGB1ITGA4 | |
| SCHEMBL5151870 | 0.86 | CXCR2 (0.46) | MAPTMEN1KMT2AALDH1A1ITGB1 | |
| SCHEMBL5156820 | 0.86 | ITGB1 (0.58) | MAPTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL5152943 | 0.85 | LPAR1 (0.54) | MEN1KMT2AALDH1A1KDM4EITGB1 | |
| SCHEMBL5153172 | 0.84 | LPAR1 (0.47) | MAPTMEN1KMT2AALDH1A1HPGD | |
| SCHEMBL5151715 | 0.83 | MEN1 (0.54) | MAPTMEN1KMT2AALDH1A1NPSR1 | |
| SCHEMBL5151950 | 0.83 | MAPT (0.51) | MAPTMEN1KMT2AALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0842196-B1 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2007-11-21 | — | — | EP | disclosed |
| US-20060166866-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2006-07-27 | — | — | US | disclosed |
| US-7001921-B1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-02-21 | — | — | US | disclosed |
| US-6875743-B1 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2005-04-05 | — | — | US | disclosed |
| US-6630512-B2 | Antiinflammatory agents; autoimmune disease | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| US-6624152-B2 | Inhibition and prevention of cell adhesion and cell adhesion-mediated pathologies. This invention relates to pharmaceutical formulations comprising these compounds and methods of using them for inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-09-23 | — | — | US | disclosed |
| US-6596687-B1 | For treatment of many inflammatory and autoimmune diseases | BIOGEN, INC. | 2003-07-22 | — | — | US | disclosed |
| US-20030083267-A1 | Cell adhesion inhibitors | BIOGEN, INC., A MASSACHUSETTS CORPORATION | 2003-05-01 | — | — | US | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| US-6306840-B1 | ANTISTICKING AGENTS OF OLIGOPEPTIDES | BIOGEN, INC. | 2001-10-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| US-6248713-B1 | OLIGOPEPTIDE FOR TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | BIOGEN, INC. | 2001-06-19 | — | — | US | disclosed |
| US-6239108-B1 | Cell adhesion inhibitors | BIOGEN, INC. | 2001-05-29 | — | — | US | disclosed |
| EP-0842196-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1998-05-20 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1997003094-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-01-30 | — | — | WO | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060166866-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | MAPT 2771/4885MEN1 1437/4885KMT2A 3376/4885 |
| US-20030083267-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | MAPT 2771/4885MEN1 1437/4885KMT2A 3376/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | MAPT 2771/4885MEN1 1437/4885KMT2A 3376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.